305 related articles for article (PubMed ID: 24472409)
1. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
3. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.
Liu S; Fang Y; Shen H; Xu W; Li H
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):756-62. PubMed ID: 23824073
[TBL] [Abstract][Full Text] [Related]
4. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
5. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
6. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
7. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
8. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
9. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
10. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.
Fu X; Tian J; Zhang L; Chen Y; Hao Q
FEBS Lett; 2012 May; 586(9):1279-86. PubMed ID: 22465665
[TBL] [Abstract][Full Text] [Related]
11. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
[TBL] [Abstract][Full Text] [Related]
13. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
14. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
15. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
van Jaarsveld MT; van Kuijk PF; Boersma AW; Helleman J; van IJcken WF; Mathijssen RH; Pothof J; Berns EM; Verweij J; Wiemer EA
Mol Cancer; 2015 Nov; 14():196. PubMed ID: 26576679
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
17. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo.
Zhang X; Wang X; Song X; Liu C; Shi Y; Wang Y; Afonja O; Ma C; Chen YH; Zhang L
Cancer Sci; 2010 Oct; 101(10):2163-70. PubMed ID: 20735432
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
